Retrosigmoidal placement of an active transcutaneous bone conduction implant: surgical and audiological perspectives in a multicentre study
Introduction. The retrosigmoidal (RS) placement of the Bonebridge system (BB) has been advocated for cases of unfavourable anatomical or clinical conditions which contraindicate transmastoid-presigmoidal positioning. However, these disadvantageous conditions, combined with the considerable dimensions of the implant, may represent a challenge, especially for surgeons with no skull base experience. Moreover, the literature reports only limited experience concerning RS implantation of the BB system. Methods. A multicentre, retrospective study was conducted to analyse the surgical and functional outcomes of a wide population of patients undergoing RS placement of the BB system by means of a surgical technique specifically developed to overcome the intraoperative issues related to this surgery. Twenty patients with conductive or mixed hearing loss and single sided deafness were submitted to RS implantation of the BB system. Results. Audiological assessment concerning the measurement of the functional and effective gain by pure-tone audiometry (28 dB HL and -12.25 dB HL, respectively) and speech audiometry (24.7 dB HL and -21 dB HL, respectively) was conducted. A high overall subjective improvement of quality of life was recorded with the Glasgow Benefit Inventory questionnaire. No major complications, such as device extrusions or other conditions requiring revision surgery, were reported during the follow-up period (median: 42 months). Conclusions. In our study, which has one of the largest cohort of patients reported in the literature, RS placement of the BB system was safe and effective. Our functional results showed comparable hearing outcomes with presigmoidal placement. The effective gain, rarely investigated in this field, may be the object of further research to improve our understanding of bone conduction mechanisms exploited by bone conduction hearing implants.
In the 16th century, Girolamo Cardano first described the transmission of sounds by bone conduction (BC) as an effective way to produce the sense of hearing 1. Based on audiological principles described many centuries ago, current BC hearing implants (BCHIs) result from the impressive advances of the modern hearing industry and are used for different types of hearing impairment: conductive or mixed forms of hearing loss and single sided deafness (SSD) 2,3. BCHIs are mainly divided into two different categories: skin-drive BCHIs and direct-drive BCHIs. For the first type of device, the vibrations are transmitted through intact skin, while in direct-drive BCHIs the vibrations are sent directly to the bone via a screw attached to the skull (percutaneous BCHI) or an active transducer implanted into the bone (transcutaneous BCHI) 2. The active transcutaneous direct-drive systems have been developed to overcome the limits of percutaneous devices (skin irritation or infections around the screw, fixture extrusion), and to avoid the skin attenuation effects of skin-drive BCHIs. Nowadays, the Bonebridge® (Med-El, Innsbruck, Austria) (BB) is the only active transcutaneous BCHI available on the market, although another device has been in development since 2013 and is currently under regulatory review 4,5. Three types of surgical placements are currently being performed for the BB housing. The most commonly used is transmastoid-presigmoid placement, in which the internal part is placed in the mastoid portion of the temporal bone (sinodural angle) 6,7. The suprameatal-middle fossa placement has been proposed in patients with aural atresia and requires the drilling of the parietal bone with complete exposure of the meninges. The lack of research on direct and long-term vibrations on the dura is in alignment with the authors’s recommendations for long-term follow-ups 8. Retrosigmoidal (RS) placement has proven to be useful in all patients in whom anatomical or clinical conditions contraindicate a presigmoidal position 9. The literature reports only limited experience concerning RS implantation of the BB system, for which surgical decision making faces many intraoperative challenges, mainly related to the device dimensions 2,3,6-10. The purpose of our study was to analyse surgical and functional outcomes in a wide population of patients undergoing RS placement of the BB system by means of a surgical technique specifically developed to overcome the intraoperative issues related to this surgery.
Materials and methods
Study design and participants
A multicentre, retrospective case series study was conducted on BCHI recipients who underwent RS placement of the BB system at three Otolaryngology tertiary referral centres between January 2013 and September 2019. Approval from the local ethics committees was obtained and all patients signed informed consent agreements before treatment. All patients met the audiological criteria suggested by the manufacturer: mild to moderate conductive hearing loss (CHL) or mixed hearing loss (MHL) with pure tone average (PTA) BC threshold (0.5, 1, 2, 3 and 4 kHz) ≤ 45 dB HL and minimum PTA air bone gap (ABG) of 30 dB, or SSD with a better ear PTA air conduction (AC) threshold ≤ 20 dB HL. Moreover, enrolment criteria involved:
- conditions that contraindicate a presigmoid-transmastoid approach:
- anatomical (protruding sigmoid sinus, low-lying middle fossa dura, contracted mastoid bone);
- clinical (chronical wet middle ear and mastoid cavity, previous canal wall down mastoidectomy, aural atresia scheduled for external ear reconstruction);
- failure of previous hearing rehabilitation surgery (e.g. stapedotomy, tympanoplasty);
- inadequate hearing rehabilitation with conventional hearing aids.
The preoperative assessment included a temporal bone CT scan and a brain MRI aimed at planning the surgical approach and excluding comorbidities that may contraindicate surgery or require radiological follow-up. All audiometric tests were performed with an Inventis Piano Plus® audiometer. Preoperatively, pure-tone AC threshold from 0.125 to 8.0 kHz and pure-tone BC threshold from 0.25 to 4.0 kHz were measured and the PTA (0.5, 1, 2, 4 kHz) was calculated. The speech reception threshold (SRT), at which 50% of the presented disyllabic words are recognised, was recorded in quiet conditions for both AC and BC. Postoperatively, a pure tone audiometry and a speech audiometry with disyllabic words in free field and quiet conditions were performed in both unaided (BB-OFF) and aided conditions (BB-ON). A noise masker by means of insert (at the non-test ear) was adopted to prevent cross hearing when necessary. As audiological outcomes, the functional gain (i.e. the difference between the postoperative unaided and aided threshold) and the effective gain (i.e. the difference between the BC threshold and the aided threshold) were evaluated by pure-tone audiometry and speech audiometry. The first fitting was planned about 1 month after surgery. Audiological follow-ups were scheduled at 3, 6, and 12 months and then yearly. The Glasgow Benefit Inventory (GBI) questionnaire was administered to each patient to evaluate items regarding the quality of life after the surgery. It consists of 18 questions, 12 of which apply to general health, 3 to physical health and 3 to social health. For each question, 5 possible answers are available (scores ranging from 1 to 5). Through a mathematical formula, four scores are then obtained: a total score and three partial scores (general health, physical health and social health). Each score ranging from -100 (worsening after surgery) through 0 (no change) to + 100 (improvement after surgery) 11.
All the surgical procedures employed the same technique, the steps of which are described below.
The conventional RS anatomical landmarks were identified to allow the positioning of the internal implanted unit (the BC floating mass transducer or BC-FMT) posteriorly to the sigmoid sinus and superiorly to the digastric fossa, where a regular bony surface was usually identified as the ideal location for the BC-FMT.
A retro-auricular reversed C-shaped incision was made (4 cm-long incision) and an anteriorly pedicled C-shaped muscular-periosteal flap was harvested to enable access to the bony area located above the digastric fossa and to create a natural anatomical division between the mastoid cavity and the BB housing. The subperiosteal pouch for the location of the coil and the magnet was obtained under the flap.
The probe (T-sizer) of the device was used to identify a suitable area for the BC-FMT placement. In the centre of the marked area, the cortical bone was removed by shaping a circular hole which diameter was smaller than the actual BC-FMT diameter (Fig. 1a,b).
A diamond burr was used to drill in the undercut position to safely explore the circumference of the surgical site. Careful drilling was needed close to the sigmoid sinus. If the sigmoid sinus was encountered, the circumference was enlarged step by step in a safer direction with the intent of obtaining the diameter required (Fig. 1c,d). The emissary mastoid vein was closed if intercepted.
A bony island between the BC-FMT and the dura mater was shaped in order to reach a suitable depth for the BC-FMT housing when necessary. Once the bone layer was obtained, it was separated from the underlying dura mater using a freer dissector. The resulting surface could be depressed, allowing complete lodging of the BC-FMT. (Fig. 1e,f).
The T-sizer was used to verify the correct positioning of the BC-FMT, and the device was inserted and fixed with two self-tapping cortical screws. The anterior pedicle muscle-periosteal flap was reconstructed with resorbable sutures and the subcutaneous layer and the skin were then closed.
Statistical analysis were performed with R software (R version 3.1.3, R Development Core Team, R Foundation for Statistical Computing, Wien, Austria). Descriptive statistics were calculated for all groups (the mean, standard deviation, median, minimum and maximum values). Normality of distributions was assessed with the Kolmogorov and Smirnov tests. An ANOVA test was ran to determine whether significant differences existed among the groups. The Tukey test was used post-hoc. The Kruskal Wallis test was used to assess the statistical significance of each GBI subscore. Significance for all statistical tests was predetermined at p < 0.05.
A total of 20 patients (11 males, 9 females, median age of 47.2 years) were included in the study. 13 patients were implanted on the right side and 7 on the left side. The aetiology, type of hearing loss, and previous otologic and surgical history were investigated (Tab. I).
Preoperative audiological assessment
10 patients with CHL (50%), 8 patients with MHL (40%) and 2 patients with SSD (10%) were identified; these latter two were not included in the statistical analysis of audiological outcomes because surgery was performed to obtain a contralateral routing of signal. Mean PTA (18 out of 20 patients) of the implant candidate’s ear was 61.5 dB HL (range 41.25-83.75 dB HL, SD: ± 13.07) for AC, 20.5 dB HL (range 6.25-33.75 dB HL, SD: ± 8.72) for BC. The ABG calculated on the PTA was 41 dB HL (range 28.75-56.25 dB HL, SD: ± 7.58). Regarding speech audiometry on the implant candidate’s ear, the mean AC SRT was 67.85 dB HL (range 55-90 dB HL, SD: ± 13.4); BC SRT was 20.35 dB HL (range 10-40 dB HL, SD: ± 9.49). The ABG SRT for the implanted side was 47.5 dB HL (range 30-70 dB HL, SD ± 10.51) (Fig. 2).
Postoperative audiological assessment
Postoperatively, in the BB-OFF setting, AC PTA was 60.8 dB HL (range 41.25-83.75 dB HL, SD: ± 12.22). The PTA threshold improved to 32.75 dB HL in the BB-ON setting (range 11.25-45 dB HL, SD: ± 8.29). The mean functional gain on pure-tone audiometry was 28 dB HL (range 13.75-45 dB HL, SD: ± 10.54). Concerning speech audiometry, the mean BB-OFF SRT was 66 dB HL (range 40-90 dB HL, SD: ± 13.32) improving up to 41.35 dB HL in the BB-ON setting (range 30-65 dB HL, SD: ± 9.54). The mean functional gain as analysed via speech audiometry was 24.7 dB HL (range 10-36 dB HL, SD: ± 8.74 – Fig. 3). The mean pure-tone effective gain (i.e. the mean difference between the BC PTA and the BB-ON PTA) was -12.25 dB HL (range -27.5-0 dB HL, SD: ± 8.82) (Fig. 3). The effective gain distribution was also selectively analysed at low (0.25, 0.5 kHz), mid (1, 2 kHz) and high frequencies (4 kHz) and resulted in -26.25 dB HL (SD: ± 5.8), -4.29 dB HL (SD: ± 6.56) and -18.57 dB HL (SD: ± 9.07) respectively. The mean effective gain calculated via speech audiometry was -21 dB HL (range -30-0 dB HL, SD: ± 8). During the follow-up (median: 42 months; range: 11-72 months) no worsening of the BC threshold occurred. About 3 months after the first fitting, a stability of the audiological gain values was observed and then confirmed at subsequent evaluations. The ANOVA and Tukey tests were ran to determine the presence of significant differences (p < 0.05) between BB-ON thresholds and BB-OFF thresholds (functional gain) and between BB-ON thresholds and BC thresholds (effective gain). Specifically, pure-tone BB-ON and BB-OFF thresholds were compared considering all frequencies between 0.25 kHz and 4 kHz. A significant difference was found for each frequency tested (p < 0.05). Functional gain was found significant (p < 0.05) by speech audiometry when BB-ON SRTs were compared with BB-OFF SRTs. Focusing on the effective gain analysed via pure-tone audiometry, a significant difference (p < 0.05) was seen between BB-ON thresholds and BC thresholds at 0.25, 0.5 and 4 kHz (Fig. 4a,c). Conversely, a significant difference was not found at 1 and 2 kHz (p > 0.05) (Fig. 4b). An overall statistically significant difference (p < 0.05) was found when BB-ON SRTs were compared with BC thresholds (Fig. 4d).
Surgery and complications
The device was correctly placed in the designated RS surgical area in all patients and it was possible to fix the implant with both screws. Specifically, a bony island was sculpted in 17 patients (85%) and lifts were used in 1 patient (5%), while the implant was directly lodged in 2 patients (10%). No major complications were observed. Minor complications included a single case of dural dehiscence that was repaired with autologous fascia. Postoperative sensorineural hearing worsening or vestibular symptoms were never observed. At the time of follow-up, none of the BB recipients experienced device extrusions or other conditions requiring revision surgery.
Quality of life assessment
Concerning the GBI questionnaire, descriptive statistics are showed in Table II. Patients showed general, physical and social health gain (p < 0.05; Fig. 5) and no significant differences were reported among the various subcategories (p > 0.05).
Our study presents one of the largest samples of patients submitted to RS implantation of the BB system reported in literature. The sample is highly homogeneous in terms of surgical technique and audiological assessment. First described by Sprinzl et al. in a European multicentre study 12, RS placement has been advocated in case of unfavourable anatomical or clinical conditions which contraindicate the presigmoidal position 9,13,14. However, these disadvantageous conditions combined with the considerable dimensions of the internal implanted unit (8.7 mm in thickness and 15.8 mm in diameter) and with the topography of the anatomical area addressed to the BC-FMT housing, make this surgical procedure challenging 7,15-17. In alignment with data from the literature, medical history of previous middle ear surgery represented the main eligibility criteria for a RS position 9 in our study. The harvesting of an anteriorly pedicled muscular-periosteal flap was developed to prevent possible contaminations from the mastoid cavity and middle ear towards the site of implantation. The surgical technique was designed to obtain an adequate bony bed for the BC-FMT housing, while avoiding hazardous drilling (especially close to the sigmoid sinus). It also prevents over-extension of the drilling surface which could compromise fixation of screws. In all BB recipients, the surgical procedure was successfully performed with a complete lodging of the BC-FMT and with its fixation with two self-tapping screws. None of the patients required revision surgery or BB explantation. A bony island was sculpted in 85% of patients, allowing adequate BC-FMT housing and concurrent protection of the dura from major complications both intra- and postoperatively. Brkic et al. 18 recently reported one of the largest studies of patients submitted to BB implantation, analysed over a 6-year follow-up period. In their experience, the authors observed an overall complication rate of 9.4% including 5 cases of explantation. Interestingly, 3 of these implants were positioned in a radical cavity, which was subsequently compromised by postoperative infections. According to the authors, a presigmoidal approach is to be preferred even in patients with history of previous radical cavities because of anatomical factors limiting RS placement. Furthermore, the same tertiary referral centre published a previous study of 19 patients in which the BC-FMT was directly coupled to the dura or sinus (7 RS placements, 12 presigmoidal/middle fossa placements). Although no adverse events were reported, the authors clarified that the risks of direct sinus/dura compression are not yet clear 19.
In our experience, the surgical technique was designed to overcome the abovementioned issues and to reduce the possibility of revision surgery or long-term untoward events. Considering audiological findings, all patients enrolled met the preoperative recommended criteria: specifically, mean BC PTA was 20.5 dB, almost 25 dB lower than the manufacturer’s indications. The effectiveness of BCHI was investigated by means of two audiological measurements: functional and effective gain. The mean PTA functional gain was found to be 28 dB HL, consistent with the results reported in the two largest series of RS implanted patients (28.9 dB and 28 dB in Ihler et al. 20 and Loader et al. 14 respectively). With regards to presigmoidal placement, our data did not reveal a significant difference in terms of mean functional gain (Gerdes et al. 21 27.5 dB; Riss et al. 22 28.8 dB). Although debated in literature, superior audiological effectiveness cannot be assessed using currently published data when the two BC-FMT surgical placements are compared 14,19,23,24. The effective gain is considered expression of the relationship between the threshold in aided condition and the patient’s cochlear reserve. Defined as the difference between the BC threshold and the aided threshold, the effective gain may result in negative values and if positive, indicates ABG overclosure. This parameter was previously measured by Donnelly et al. 25 to evaluate the effectiveness of different types of active middle ear implants and by van Barneveld et al. 26 to define fitting ranges for BC devices. To the best of our knowledge, only one study has reported this parameter in BCHI recipients 18, although it was not object of further analysis. In our experience, the mean pure-tone effective gain was -12.25 dB HL, although it showed a different statistical distribution when selectively analysed at low, mid and high frequencies. In particular, the highest values were measured at 1-2 kHz (-4.29 dB HL) where a significant difference between the BB-ON thresholds and the BC thresholds was not found. These observations, apparently, do not relate to power output issues. What seems to limit the BB fitting range on certain frequencies are unpleasant sound distortions and annoying vibratory perceptions 26. The RS placement itself, does not seem to be related to these findings, since our audiological results have shown to be comparable with current literature data for presigmoid positioning. Furthermore, a significant improvement in the quality of life was recorded in all patients as suggested by the total and partial GBI scores. We are, nonetheless, aware that some concerns regarding our study may arise. The retrospective and multicentric nature of the study may be considered a limitation in terms of heterogeneity of the series. However, the adoption of common enrolment criteria and a standardised surgical technique and the uniformity of data analysis minimise this bias. Additionally, the introduction of an uncommonly used audiological measurement such as the effective gain may preclude comparison with the current literature.
RS placement of the BB system was seen to be safe and effective, thus constituting in a valid surgical alternative when the presigmoidal position is not advised. However, it may represent a challenge, especially for surgeons with no skull base experience. The surgical technique introduced was developed to define the main surgical steps of RS placement in order to obtain a complete lodging of the internal implanted unit, avoiding untoward events both intra- and postoperatively, even after long-term follow-up. Our functional results show comparable hearing outcomes with presigmoidal placement, in contrast to authors who argue a greater efficacy of one of the two positions. The effective gain, rarely investigated in this field of literature, may be object of future research to improve our understanding of BC mechanisms exploited by the BCHIs.
Figures and tables
|Patient||Sex||Age||Hearing loss||Pathology||Previous surgery(BB side)||Implanted side||Bonyisland|
|1||M||47||Bilateral MHL||Bilateral cholesteatoma||CWD TPL||Right||Not required|
|2||M||60||Bilateral MHL||Bilateral cholesteatoma||CWD TPL||Right||Yes|
|3||M||23||Bilateral CHL||Atresia auris (BB side) + cholesteatoma||None||Left||Yes|
|4||M||46||Bilateral MHL||Bilateral COM||CWU TPL||Right||Yes|
|5||F||52||Bilateral CHL||Bilateral cholesteatoma||CWD TPL||Left||Yes|
|7||F||31||Bilateral CHL||Bilateral atresia auris||None||Left||Yes|
|8||F||49||Bilateral MHL||Cholesteatoma (BB side) + COM||CWD TPL||Right||Yes|
|10||F||61||Bilateral MHL||Bilateral cholesteatoma||CWD TPL||Left||Yes|
|11||M||64||Bilateral MHL||Bilateral COM||CWU TPL||Right||Not required|
|12||M||76||MHL (BB side) + SNHL||Cholesteatoma||Lateral petrosectomy||Right||Yes|
|13||F||67||Bilateral MHL||Bilateral cholesteatoma||CWD TPL||Right||Yes|
|14||F||14||Unilateral CHL||Cholesteatoma||CWD TPL||Right||Yes|
|15||M||37||Bilateral CHL||Bilateral cholesteatoma||Lateral petrosectomy||Left||Yes|
|16||F||33||Bilateral CHL||Bilateral otosclerosis||Stapedotomy||Right||Yes|
|17||M||39||Unilateral CHL||Cholesteatoma (BB side) + COM||Lateral petrosectomy||Right||Yes|
|18||F||47||CHL (BB side) + MHL||Cholesteatoma (BB side) + COM||CWD TPL||Right||Yes|
|19||M||57||CHL (BB side) + SNHL||Cholesteatoma (BB side)||CWD TPL||Left||Yes|
|20||M||48||CHL||Cholesteatoma||CWU TPL||Left||No (lifts 2 mm)|
- Berger KW. Early bone conduction hearing aid devices. Arch Otolaryngol. 1976; 102:315-8. DOI
- Reinfeldt S, Håkansson B, Taghavi H. New developments in bone-conduction hearing implants: a review. Med Devices (Auckl). 2015; 8:79-93. DOI
- Canale A, Boggio V, Albera A. A new bone conduction hearing aid to predict hearing outcome with an active implanted device. Eur Arch Otorhinolaryngol. 2019; 276:2165-70. DOI
- Eeg-Olofsson M, Håkansson B, Reinfeldt S. The bone conduction implant – first implantation, surgical and audiologic aspects. Otol Neurotol. 2013; 35:679-85. DOI
- Håkansson B, Reinfeldt S, Persson AC. The bone conduction implant – a review and 1-year follow-up. Int J Audiol. 2019; 58:945-55. DOI
- Sprinzl GM, Wolf-Magele A. The Bonebridge Bone Conduction Hearing Implant: indication criteria, surgery and a systematic review of the literature. Clin Otolaryngol. 2016; 41:131-43. DOI
- Wimmer W, Gerber N, Guignard J. Topographic bone thickness maps for Bonebridge implantations. Eur Arch Otorhinolaryngol. 2015; 272:1651-8. DOI
- Der C, Bravo-Torres S, Pons N. Active transcutaneous bone conduction implant: middle fossa placement technique in children with bilateral microtia and external auditory canal atresia. Otol Neurotol. 2018; 39:342-8. DOI
- Lassaletta L, Sanchez-Cuadrado I, Muñoz E. Retrosigmoid implantation of an active bone conduction stimulator in a patient with chronic otitis media. Auris Nasus Larynx. 2014; 41:84-7. DOI
- Barbara M, Perotti M, Gioia B. Transcutaneous bone-conduction hearing device: audiological and surgical aspects in a first series of patients with mixed hearing loss. Acta Otolaryngol. 2013; 133:1058-64. DOI
- Robinson K, Gatehouse S, Browning GG. Measuring patient benefit from otorhinolaryngological surgery and therapy. Ann Otol Rhinol Laryngol. 1996; 105:415-22. DOI
- Sprinzl G, Lenarz T, Ernst A. First European multicenter results with a new transcutaneous bone conduction hearing implant system: short-term safety and efficacy. Otol Neurotol. 2013; 34:1076-83. DOI
- Lassaletta L, Calvino M, Zernotti M. Postoperative pain in patients undergoing a transcutaneous active bone conduction implant (Bonebridge). Eur Arch Otorhinolaryngol. 2016; 273:4103-10. DOI
- Loader B, Sterrer E, Reichmayr C. Direct comparison of mastoidal and retrosigmoidal placement of a transcutaneous bone conduction device after canal wall down tympanoplasty. Clin Otolaryngol. 2018; 43:1603-6. DOI
- Bianchin G, Bonali M, Russo M. Active bone conduction system: outcomes with the Bonebridge transcutaneous device. ORL. 2015; 77:17-26. DOI
- Canzi P, Marconi S, Manfrin M. From CT scanning to 3D printing technology: a new method for the preoperative planning of a transcutaneous bone-conduction hearing device. Acta Otorhinolaryngol Ital. 2018; 38:251-6. DOI
- Law EKC, Bhatia KSS, Tsang WSS. CT pre-operative planning of a new semi-implantable bone conduction hearing device. Eur Radiol. 2016; 26:1686-95. DOI
- Brkic FF, Riss D, Scheuba K. Medical, technical and audiological outcomes of hearing rehabilitation with the bonebridge transcutaneous bone-conduction implant: a single-center experience. J Clin Med. 2019; 8:1614. DOI
- Vyskocil E, Riss D, Arnoldner C. Dura and sinus compression with a transcutaneous bone conduction device – hearing outcomes and safety in 38 patients. Clin Otolaryngol. 2017; 42:1033-8. DOI
- Ihler F, Blum J, Berger MU. The prediction of speech recognition in noise with a semi-implantable bone conduction hearing system by external bone conduction stimulation with headband: a prospective study. Trends Hear. 2016; 20:1-12. DOI
- Gerdes T, Salcher RB, Schwab B. Comparison of audiological results between a transcutaneous and a percutaneous bone conduction instrument in conductive hearing loss. Otol Neurotol. 2016; 37:685-91. DOI
- Riss D, Arnoldner C, Baumgartner WD. Indication criteria and outcomes with the Bonebridge transcutaneous bone-conduction implant. Laryngoscope. 2014; 124:2802-6. DOI
- Salcher R, Zimmermann D, Giere T. Audiological results in SSD with an active transcutaneous bone conduction implant at a retrosigmoidal position. Otol Neurotol. 2017; 38:642-7. DOI
- Schmerber S, Deguine O, Marx M. Safety and effectiveness of the Bonebridge transcutaneous active direct-drive bone-conduction hearing implant at 1-year device use. Eur Arch Otorhinolaryngol. 2017; 274:1835-51. DOI
- Donnelly NP, Pennings RJE. Hearing rehabilitation with active middle ear implants. Adv Otorhinolaryngol. 2018; 81:43-56. DOI
- Van Barneveld DCPBM, Kok HJW, Noten JFP. Determining fitting ranges of various bone conduction hearing aids. Clin Otolaryngol. 2018; 43:68-75. DOI
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale , 2021
- Abstract viewed - 488 times
- PDF downloaded - 236 times